Drug Profile
Research programme: regenerative therapeutics - La Jolla Pharmaceutical
Alternative Names: LJP-1485; Regenerative Immunophilin LigandsLatest Information Update: 25 May 2012
Price :
$50
*
At a glance
- Originator GliaMed
- Developer La Jolla Pharmaceutical Company
- Class Small molecules
- Mechanism of Action Immunophilin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Scars
Most Recent Events
- 30 Mar 2012 Discontinued - Preclinical for Scars in USA (unspecified route)
- 06 Apr 2011 Preclinical trials in Scars in USA (unspecified route)